APP and Alzheimer disease: The simplest approach to accomplish this is to utilize the current transgenic models overexpressing human AβPP: they are, after all, well on their way to becoming AD models in that they exhibit the neuronal ISR elicited by AβPP-derived iAβ; all that is needed is to enable operation of the AβPP-independent C99 production pathway.